Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.61 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.61 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.61 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.61 |
| ▸ | RARB | P10826 | 2/20 | 0.61 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.61 |
| ▸ | ALB | P02768 | 1/20 | 0.61 |
| ▸ | ESR1 | P03372 | 1/20 | 0.61 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.61 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.61 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.61 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.61 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29394323 | 1.00 | PTGS2 (0.61) | PTGS2PTGS1AKR1C3LMNACYP2C9 | |
| SCHEMBL14240874 | 1.00 | PTGS2 (0.61) | PTGS2PTGS1AKR1C3LMNACYP2C9 | |
| Methyl Alcohol SCHEMBL28195945 | 0.98 | PTGS2 (0.59) | PTGS2PTGS1AKR1C3LMNACYP2C9 | |
| SCHEMBL28377476 | 0.95 | RARB (0.59) | PTGS2PTGS1AKR1C3LMNACYP2C9 | |
| SCHEMBL27700219 | 0.93 | RARB (0.57) | PTGS2PTGS1AKR1C3LMNACYP2C9 | |
| SCHEMBL11426419 | 0.91 | PTGS2 (0.67) | PTGS2PTGS1AKR1C3LMNACYP2C9 | |
| SCHEMBL11424011 | 0.91 | PTGS2 (0.67) | PTGS2PTGS1AKR1C3LMNACYP2C9 | |
| Butylbenzyl SCHEMBL28123906 | 0.90 | PTGS2 (0.51) | PTGS2PTGS1AKR1C3LMNACYP2C9 | |
| SCHEMBL471134 | 0.89 | PTGS2 (0.65) | PTGS2PTGS1AKR1C3LMNACYP2C9 | |
| SCHEMBL11425385 | 0.89 | PTGS2 (0.65) | PTGS2PTGS1AKR1C3LMNACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114062554-B | Analysis method for simultaneously measuring related substances of acetaminophen ibuprofen | 山东百诺医药股份有限公司 | 2023-07-21 | — | — | CN | claimed |
| CN-114062554-A | Analysis method for simultaneously determining acetaminophen ibuprofen-related substances | 山东百诺医药股份有限公司 | 2022-02-18 | — | — | CN | claimed |
| CN-104042596-A | Ibuprofen granule and preparation method thereof | HARBIN HUARUI BIOCHEMICAL PHARMACEUTICAL CO LTD | 2014-09-17 | — | — | CN | claimed |
| CN-102716069-A | Injection liquid containing ibuprofen and preparation process of injection liquid | WUXI KFT PHARMACEUTICAL TECHNOLOGY CO LTD | 2012-10-10 | — | — | CN | claimed |
| CN-119715820-A | Method for detecting ibuprofen related substances in ibuprofen renin tablets | 北京济美堂医药研究有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-117143091-A | HBV core protein degradation agent based on hydrophobic tag technology and preparation method and application thereof | 山东大学 | 2023-12-01 | — | — | CN | disclosed |
| CN-114062554-B | Analysis method for simultaneously measuring related substances of acetaminophen ibuprofen | 山东百诺医药股份有限公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-114062554-A | Analysis method for simultaneously determining acetaminophen ibuprofen-related substances | 山东百诺医药股份有限公司 | 2022-02-18 | — | — | CN | disclosed |
| CN-112479855-A | Preparation method of ibuprofen impurity B | 艾希尔（深圳）药物研发有限公司 | 2021-03-12 | — | — | CN | disclosed |
| CN-112441902-A | Preparation method of ibuprofen impurity F | 艾希尔（深圳）药物研发有限公司 | 2021-03-05 | — | — | CN | disclosed |
| CN-108619087-A | A kind of pharmaceutical composition containing brufen | 长春海悦药业股份有限公司 | 2018-10-09 | — | — | CN | disclosed |
| CN-107648339-A | A kind of medicine for reducing brufen clinical treatment rheumatic arthritis side effect | 刘柱 | 2018-02-02 | — | — | CN | disclosed |
| US-20090214648-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING IBUPROFEN AND DIPHENHYDRAMINE | DR. REDDY'S LABORATORIES, INC. | 2009-08-27 | — | — | US | disclosed |
| US-20090214648-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING IBUPROFEN AND DIPHENHYDRAMINE | DR. REDDY'S LABORATORIES, INC. | 2009-08-27 | — | — | US | disclosed |
| US-20080154049-A1 | for acylation of an aromatic compound, comprising reacting an aromatic compound and an acylating agent of the carboxylic acid type, in the presence of a Lewis acid and of a silylated reagent selected from the group consisting of halosilanes and halosiloxanes. | SHASUN PHARMA SOLUTIONS LIMITED (GB) | 2008-06-26 | — | — | US | disclosed |
| US-20070265344-A1 | Non-steroidal anti-inflammatory oral powder and liquid preparations for administration to animals | PHARMACEUTICAL SOLUTIONS, INC. | 2007-11-15 | — | — | US | disclosed |
| EP-1452169-B1 | AQUEOUS BASE LIQUID PHARMACEUTICAL COMPOSITIONS IN SUSPENSION FORM FOR THE ORAL ADMINISTRATION OF IBUPROFEN | FARMALIDER SA (ES) | 2007-01-24 | — | — | EP | disclosed |
| EP-1452169-A1 | AQUEOUS BASE LIQUID PHARMACEUTICAL COMPOSITIONS IN SUSPENSION FORM FOR THE ORAL ADMINISTRATION OF IBUPROFEN | Farmalider, S.A. (ES) | 2004-09-01 | — | — | EP | disclosed |
| WO-1998033496-A1 | SULPHONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1998-08-06 | — | — | WO | disclosed |
| US-4623736-A | INTERMEDIATES FOR ANALGESICS | THE UPJOHN COMPANY (US) | 1986-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265344-A1 | Non-steroidal anti-inflammatory oral powder and liquid preparations for administration to animals | PTGES, PTGS1, IL1B | PTGS2 9/4885PTGS1 2/4885AKR1C3 2544/4885 |
| US-20090214648-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING IBUPROFEN AND DIPHENHYDRAMINE | HRH1, HRH4, HRH2 | PTGS2 32/4885PTGS1 10/4885AKR1C3 2487/4885 |
| US-20080154049-A1 | for acylation of an aromatic compound, comprising reacting an aromatic compound and an acylating agent of the carboxylic acid type, in the presence of a Lewis acid and of a silylated reagent selected from the group consisting of halosilanes and halosiloxanes. | AADAC, APEH, DDC | PTGS2 4658/4885PTGS1 4613/4885AKR1C3 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.